JPH05262660A - Tricomponent formulation - Google Patents

Tricomponent formulation

Info

Publication number
JPH05262660A
JPH05262660A JP3334854A JP33485491A JPH05262660A JP H05262660 A JPH05262660 A JP H05262660A JP 3334854 A JP3334854 A JP 3334854A JP 33485491 A JP33485491 A JP 33485491A JP H05262660 A JPH05262660 A JP H05262660A
Authority
JP
Japan
Prior art keywords
ginseng
pantethine
vitamin
effect
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3334854A
Other languages
Japanese (ja)
Inventor
Yoshiaki Nakai
義昭 中井
Naoki Imoto
直樹 井本
Toshio Murakami
敏男 村上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP3334854A priority Critical patent/JPH05262660A/en
Publication of JPH05262660A publication Critical patent/JPH05262660A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To provide a formulation having the effects of improving alcohol metabolism and feeling of cold as well as nutrients supply and analeptic effect. CONSTITUTION:When conventionally known pantethine, ginseng and vitamin E are suitably formulated, the resultant preparation develops synergistic effects, namely improvement in alcohol metabolism, feeling of cold and indefinite complaints in addition to nutrients supply and analeptic effects. Accordingly, the resultant formulation is effective not only for analeptic effect and nutrient enrichment but also for improvements in alcohol metabolism, feeling of cold and the indefinite complaints.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、パンテチン、朝鮮人参
及びビタミンEの三成分を配合した合剤に関する。
FIELD OF THE INVENTION The present invention relates to a mixture containing pantethine, ginseng and vitamin E.

【0002】[0002]

【従来の技術】近年、高齢化社会の進行に伴い、或は社
会構造の複雑化に伴い、特に、熟年以後の健康管理は、
重要な社会問題となっており、そのために各種滋養強壮
剤が開発されている。
2. Description of the Related Art In recent years, with the progress of an aging society or the complexity of the social structure, in particular, health management after middle age is
It has become an important social problem, and various nutritional tonics have been developed for that purpose.

【0003】滋養強壮を目的とした薬剤には、漢方処方
に基づく製剤、生薬を主剤とする製剤、総合ビタミン
剤、ビタミン類にアミノ酸、生薬、臓器抽出物等を配合
した製剤等があり、セルフ・メディケーションの一環と
して、健康維持・増進をめざし服用されている。しか
し、これら滋養強壮を目的とした薬剤には、アルコール
代謝の改善に有効なものはない。
[0003] Drugs for nutritional tonic include preparations based on Kampo prescription, preparations based on crude drugs, multivitamin preparations, preparations in which amino acids, crude drugs and organ extracts are mixed with vitamins.・ As part of meditation, it is taken to maintain and improve health. However, none of these drugs for nutritional tonic are effective in improving alcohol metabolism.

【0004】[0004]

【発明が解決しようとする課題】そこで、本発明者らは
従来の滋養強壮剤には認められなかった効果、すなわ
ち、滋養強壮効果に加え、アルコール代謝改善、冷え症
の改善及び不定愁訴の改善にも非常に効果を有する合剤
を提供するものである。
Therefore, the present inventors have found that, in addition to the effect of nourishing and tonicity, which is not observed in the conventional nourishing and tonicative agents, the improvement of alcohol metabolism, the improvement of cold sensitivity and the improvement of indefinite complaints are achieved. Also provides a highly effective mixture.

【0005】[0005]

【課題を解決するための手段】本発明の合剤の有効成分
である三成分は各々公知の物質であり、従来独立して使
用されている。すなわち、パンテチンは脂質代謝改善剤
として著名な医薬品であり、朝鮮人参は各種薬理効果を
あわせもつものとして滋養強壮剤として古くより使われ
ており、またビタミンEは抗酸化作用による動脈硬化の
防止、栄養障害の改善等に使用されている。
The three components which are the active ingredients of the mixture of the present invention are known substances and have been conventionally used independently. That is, pantethine is a prominent drug as a lipid metabolism improving agent, ginseng has long been used as a nourishing and tonic agent with various pharmacological effects, and vitamin E is used to prevent arteriosclerosis due to its antioxidative effect. It is used to improve nutritional disorders.

【0006】そこで、本発明者らは鋭意研究を重ねた結
果、これら公知の三つの化合物を適切に配合した合剤を
製した場合、それぞれ単独使用における効果より、はる
かに優れた効果が期待しうること、及び単独使用では期
待しえなかった効果、すなわち、アルコール代謝の改
善、冷え症の改善及び不定愁訴の改善に有効なことを見
いだし、本発明を完成したものである。
[0006] Therefore, as a result of intensive studies, the present inventors have expected that when a mixture containing these three known compounds is prepared, the effects are far superior to those obtained by using them alone. The present invention has been completed by discovering the effects that were not expected when used alone or alone, that is, effective in improving alcohol metabolism, improving cold sensation, and improving indefinite complaints.

【0007】本発明の合剤を製するには、パンテチン、
朝鮮人参及びビタミンEの三成分を適量比で混合し、必
要ならば通常使用される適当なる製剤上の添加剤、例え
ば、トウモロコシデンプン、カルボキシルメチルセルロ
ース等を加え、好ましい剤型、すなわち、錠剤、顆粒
剤、カプセル剤等とすれば良い。
To produce the mixture of the present invention, pantethine,
Ginseng and vitamin E are mixed in an appropriate amount ratio, and if necessary, an appropriate formulation additive such as corn starch, carboxymethyl cellulose, etc., which is usually used, is added to obtain a preferable dosage form, that is, tablets, granules. It may be used as an agent or a capsule.

【0008】混合比としては、前三者の比を約1:2〜
15:0.05〜0.3とするのが好ましく、この際使
用される各主成分は下記のものが使用される。
The mixing ratio of the former three is about 1: 2.
It is preferable to set it to 15: 0.05 to 0.3, and the following main components are used as each main component used in this case.

【0009】すなわち、パンテチンは含量規格で90〜
115%のものが、ビタミンEは同じく90〜110%
のものが使用され、朝鮮人参は日局規格(第10改正)
に適するニンジン(人参)、コウジン(紅参)が使用し
え、サポニン含量が安定した4〜6年ものが好ましく使
用される。
That is, pantethine has a content standard of 90-
115% is the same as vitamin E 90-110%
Used ginseng, Japanese ginseng standard (10th revision)
Suitable carrots (carrots) and ginseng (red ginseng) can be used, and those having a stable saponin content for 4 to 6 years are preferably used.

【0010】かくして製した本発明の合剤が、通常の流
通保存環境条件下では安定であることを室温及び40
℃、75%R.Hの条件下における安定試験(外観、確
認試験、含量、崩壊試験及び吸湿増量)で確認した。
The thus prepared mixture of the present invention is stable under ordinary conditions of distribution and storage at room temperature and 40%.
C, 75% R.C. It was confirmed by a stability test under H conditions (appearance, confirmation test, content, disintegration test and moisture absorption increase).

【0011】又、本発明の合剤の安全性についても検討
した結果、極めて安全であることを確認した。すなわ
ち、ddY系マウス雌雄1群各10匹に、薬物2.5g
/kg、5.0g/kgを0.5%CMCに懸濁し、経
口投与した急性毒性試験の結果、LD50値は5g/kg
以上であった。すなわち、両薬剤群とも実験期間中死亡
例が見られず、14日間の観察期間を通じて行動及び外
観の異常は観察されなかった。又、屠殺後の剖検による
肉眼的所見にも何ら異常は認められなかった。又、dd
Y系マウスを用いた正常動物の行動に及ぼす影響にて単
回投与並びに連続20日間投与ともに、躯幹緊張度、握
力、運動協調性、自発運動量及び探索動作等コントロー
ル群と何らの差も認められなかった。
As a result of examining the safety of the mixture of the present invention, it was confirmed that it is extremely safe. That is, each group of 10 males and females of the ddY mouse has 2.5 g of the drug.
/ Kg, 5.0 g / kg were suspended in 0.5% CMC and orally administered. As a result of acute toxicity test, LD 50 value was 5 g / kg.
That was all. That is, in both drug groups, no deaths were observed during the experimental period, and no abnormalities in behavior and appearance were observed during the observation period of 14 days. In addition, no abnormality was observed in the gross findings by autopsy after slaughter. Also, dd
With regard to the effects on the behavior of normal animals using Y mice, there was no difference between the single administration and the administration for 20 consecutive days, such as trunk tone, grip strength, motor coordination, spontaneous motor activity and exploratory movement, etc. There wasn't.

【0012】また、健康人12名に1日量の1.5倍量
を運動負荷後8日間連続投与した臨床薬理試験にて、何
らの副作用も認められなかった。
Further, in a clinical pharmacological test in which 12 healthy subjects were continuously administered 1.5 times the daily dose for 8 days after exercise, no side effects were observed.

【0013】更に、後述する約200名の臨床評価試験
にて、2例に軽度の胃腸症状が認められたのみであり、
極めて安全な薬剤であった。
Further, in a clinical evaluation test of about 200 people described later, only 2 cases of mild gastrointestinal symptoms were observed,
It was an extremely safe drug.

【0014】[0014]

【発明の効果】本発明の合剤は、特にアルコール代謝改
善、冷え症改善及び不定愁訴の改善に有効な滋養強壮剤
に関する。
INDUSTRIAL APPLICABILITY The combination of the present invention relates to a nourishing tonic agent which is particularly effective in improving alcohol metabolism, improving cold sensation and improving indefinite complaints.

【0015】[0015]

【試験例】本発明の合剤の優れた効果は、下記試験例に
て具体的に示される。
TEST EXAMPLE The excellent effect of the mixture of the present invention is specifically shown in the following test example.

【0016】試験例1:基礎薬理試験 動物にアルコール負荷のほか強制運動(ロープ登り)、
水上宙吊り、水没拘束などの種々のストレスを負荷し、
これに対する薬剤の影響を行動薬理学的指標等を用いて
検討した。
Test Example 1: Basic Pharmacological Test In addition to alcohol load on animals, forced exercise (rope climbing),
Apply various stress such as hanging on the water, restraining submersion in water,
The effect of the drug on this was examined using behavioral pharmacological indexes and the like.

【0017】・使用した薬剤と投与量(mg/kg
P.O) 本配合剤(Aと略す):450、250 パンテチン(Pと略す):90 乾燥コウジンエキス(Gと略す):250 酢酸d−α−トコフェロール(Tと略す):50
The drug used and the dose (mg / kg
P. O) This compounding agent (abbreviated as A): 450, 250 Pantethine (abbreviated as P): 90 Dried ginseng extract (abbreviated as G): 250 d-α-tocopherol acetate (abbreviated as T): 50

【0018】(1)「アルコール代謝の改善」に関連し
た薬理作用 アルコール負荷に対する運動協調性試験(回転棒) アルコール負荷からの回復の状態を知る目的でマウスに
40%アルコール0.1ml/10g体重(人体換算:
ウイスキーボトル約1本相当)を経口投与し、回転棒
(ローターロッド)上の滞在時間を経時的に測定して運
動協調性の回復度を検討した。結果を以下の表に示す。
(1) Pharmacological action related to "improvement of alcohol metabolism" Exercise coordination test for alcohol load (rotating rod) For the purpose of knowing the recovery state from alcohol load, 40% alcohol 0.1 ml / 10 g body weight was given to mice. (Human body conversion:
Oral administration of whiskey bottles) was performed, and the staying time on the rotating rod (rotor rod) was measured over time to examine the degree of recovery of motor coordination. The results are shown in the table below.

【0019】[0019]

【表1】 [Table 1]

【0020】上記結果より明らかなように、本試験にお
いて効果の優れた(有意差のある)成分はパンテチン
(P)であったが、配合剤(A)に相乗効果が見られ
た。
As is clear from the above results, pantetine (P) was the most effective (significantly different) component in this test, but the compounding agent (A) showed a synergistic effect.

【0021】(2)「冷え症の改善」に関連した薬理作
用 宙吊りによる体温(直腸温)低下に対する拮抗 マウスを水上に宙吊りすると疲労と水のため体温低下を
起こすが、これに対する薬剤の影響を見た。
(2) Pharmacological action related to "improvement of cold sensation" Antagonism of decrease in body temperature (rectal temperature) caused by hanging in suspension When a mouse is suspended in water, the body temperature is lowered due to fatigue and water. It was

【0022】水上宙吊りストレス負荷後の体温低下抑制
に関しては、各単味成分に有意の効果は認められなかっ
たが、配合剤(A)では有意の効果が認められた。結果
を以下の表に示す。
Regarding the suppression of the decrease in body temperature after the stress of suspension on the water, each plain component had no significant effect, but the combination agent (A) showed a significant effect. The results are shown in the table below.

【0023】[0023]

【表2】 [Table 2]

【0024】(3)「不定愁訴の改善」に関連した薬理
作用 ストレス潰瘍に対する抑制作用 ラットに水没拘束による強いストレスを加え、そのため
に生ずる胃潰瘍を指標として本配合剤の効果を検討し
た。
(3) Pharmacological action related to "improvement of indefinite complaints" Inhibitory action against stress ulcer Strong stress due to restraint in water was applied to rats, and the effect of the present combination agent was examined by using the gastric ulcer caused by the stress as an index.

【0025】〜実験方法〜 ラット(1群):10匹(単回投与) 12匹(連続10回投与) 水中拘束時間:7時間 薬剤投与量:P:100、300mg/kg G:300、1000mg/kg T:100、300mg/kg A:450mg/kg(常用量の60倍)-Experimental Method- Rats (1 group): 10 (single dose) 12 (consecutive 10 doses) Restraint time in water: 7 hours Drug dose: P: 100, 300 mg / kg G: 300, 1000 mg / Kg T: 100, 300 mg / kg A: 450 mg / kg (60 times the normal dose)

【0026】〜効果の判定〜 水没拘束後直ちに開腹して、胃壁に生じた潰瘍につき赤
色部(炎症部)と黒色陥凹部(びらん部)にわけ、潰瘍
指数(Ulcer index )によって評価した。
-Determination of Effect- The laparotomy was performed immediately after submersion in water, and the ulcer formed on the stomach wall was divided into a red part (inflamed part) and a black recess (erosed part) and evaluated by the ulcer index.

【0027】水没拘束ストレスによる潰瘍の抑制作用
は、単味成分では大量トコフェロール(T.100m
g)に認められた程度で全般に弱かった。
The ulcer inhibitory action due to the submersion restraint stress is that a large amount of tocopherol (T.
It was generally weak as observed in g).

【0028】しかし、配合剤(A)は、単回投与、連続
投与共に有意の差をもって有効性が認められた。結果を
以下の表に示す。
However, the effectiveness of the combination drug (A) was recognized with a significant difference in both single and continuous administration. The results are shown in the table below.

【0029】[0029]

【表3】 [Table 3]

【0030】[0030]

【表4】 [Table 4]

【0031】[0031]

【表5】 [Table 5]

【0032】(4)「滋養強壮」に関連した薬理作用 強制運動負荷に対する影響(ロープ登り) マウスを用いて毎日1時間、14日連続したロープ登り
運動(登上距離4m/分、240m/時)をさせ、薬剤
は毎日運動後に与え、その遂行能力(疲労回復度)を検
討した。
(4) Pharmacological action related to "nutrition tonic" Effect on forced exercise load (rope climbing) Rope climbing exercise (climbing distance 4 m / min, 240 m / hour) for 1 hour and 14 days continuously using mice ), The drug was given every day after exercise, and its performance (fatigue recovery) was examined.

【0033】長期間(14日)連続の強制運動(ロープ
登り)からの回復に関しては、配合剤(A)は有意の差
をもって有効であった。特に、その傾向は後半期に顕著
であった。結果を以下に示す。
The combination (A) was effective with a significant difference in recovery from long-term (14 days) continuous forced exercise (rope climbing). Especially, the tendency was remarkable in the latter half. The results are shown below.

【0034】[0034]

【表6】 [Table 6]

【0035】水上宙吊り後の学習の再現に対する影響
(明暗箱法) 学習させたマウスを1日1時間、4日連続鼻面が水面に
接するように宙吊りにし、激しいストレスと疲労後に薬
剤を与えて、明暗箱を用いて学習の再現をさせ、その記
憶度を検討した。結果を以下の表に示す。
Effect on Reproduction of Learning after Suspension on the Water (Light and Dark Box Method) The learned mice were suspended for one hour and four days a day so that the nose surface was in contact with the water surface, and the drug was given after intense stress and fatigue, The learning was reproduced using a light-dark box and the memory was examined. The results are shown in the table below.

【0036】[0036]

【表7】 [Table 7]

【0037】なお、水上宙吊りストレス負荷後の記憶の
再現試験で、有効性の認められた単味成分は人参(G)
のみであったが、配合剤(A)も有意さをもって有効で
あった。
In the memory reproduction test after the stress suspended in the water, the simple component which was recognized to be effective was ginseng (G).
However, compounding agent (A) was also effective with significance.

【0038】水上宙吊り後の性行動障害からの回復に
対する影響 マウスを1日30分〜2時間連続14日間、と同様に
して水上に宙吊りにし、その激しいストレスと疲労を与
えた後、薬剤を与え、翌朝の性行動の度合い(ウマ乗り
行動、挿入回数)を検討した。
Effect on Recovery from Sexual Behavior Disorders after Suspension on the Water Mice were suspended on the water for 30 minutes to 2 hours a day for 14 consecutive days in the same manner, and after severe stress and fatigue, the drug was given. , Next morning, the degree of sexual behavior (horse riding behavior, number of insertions) was examined.

【0039】水上宙吊りストレス負荷後の性行動障害か
らの回復に対しては配合剤(A)は有意に有効であっ
た。結果を以下の表に示す。
The combination drug (A) was significantly effective in recovering from sexual behavior disorder after stress suspension on the water. The results are shown in the table below.

【0040】[0040]

【表8】 [Table 8]

【0041】[0041]

【表9】 [Table 9]

【0042】試験例2:臨床評価試験 予備試験の結果、本配合剤の有効性と安全性についての
予測が得られたので、全国8機関で本試験が実施され
た。同一プロトコール、調査表(医師用)、健康に関す
るアンケート用紙(患者用)にて全例196例を収集
し、解析・評価した結果は以下のとおりである。
Test Example 2: Clinical Evaluation Test As a result of the preliminary test, the efficacy and safety of this drug combination were predicted, so this test was conducted at 8 institutions nationwide. The results obtained by collecting, analyzing and evaluating 196 cases of all cases using the same protocol, survey table (for doctors) and health questionnaire sheet (for patients) are as follows.

【0043】総合評価では、やや改善以上が82.5%
で、改善以上でも37.6%を示した。
In the comprehensive evaluation, 82.5% is a little improvement or more.
Even after the improvement, 37.6% was shown.

【0044】症状別効果では食欲不振、悪酔い、腰痛、
イライラ感、冷え、便秘等に有効性が見られた。投与前
重症度別改善度ではほとんどの症状において、重症度の
高いものほど、投与後改善度が大であった。性別では、
女性の方は疲労感、肩こり等の改善が、男性の方は心悸
亢進等の改善がより大であった。結果を以下の表に示
す。
By the effect according to the symptom, anorexia, sickness, low back pain,
Effectiveness was seen in irritability, coldness, constipation, etc. In most of the symptoms of pre-dose severity improvement, the higher the severity, the greater the post-dose improvement. By gender,
Females had greater improvement in fatigue and stiff shoulders, while males had greater improvement in heart palpitations. The results are shown in the table below.

【0045】[0045]

【表10】 [Table 10]

【0046】[0046]

【表11】 [Table 11]

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31:78 8314−4C 31:355) 7252−4C ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location A61K 31:78 8314-4C 31: 355) 7252-4C

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】パンテチン、朝鮮人参及びビタミンEの三
成分を配合した合剤
1. A mixture containing three components of pantethine, ginseng and vitamin E.
【請求項2】パンテチン、朝鮮人参及びビタミンEの三
成分の配合比が1:2〜15:0.05〜0.3である
請求項1に記載された合剤
2. The mixture according to claim 1, wherein the compounding ratio of the three components of pantethine, ginseng and vitamin E is 1: 2 to 15: 0.05 to 0.3.
【請求項3】パンテチン、朝鮮人参及びビタミンEの三
成分を配合したアルコール代謝改善剤
3. An alcohol metabolism improving agent containing three components of pantethine, ginseng and vitamin E.
【請求項4】パンテチン、朝鮮人参及びビタミンEの三
成分を配合した冷え症改善剤
4. An agent for improving chills, which contains three components of pantethine, ginseng and vitamin E.
【請求項5】パンテチン、朝鮮人参及びビタミンEの三
成分を配合した不定愁訴改善剤
5. An agent for improving indefinite complaints which contains three components of pantethine, ginseng and vitamin E.
JP3334854A 1991-12-18 1991-12-18 Tricomponent formulation Pending JPH05262660A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3334854A JPH05262660A (en) 1991-12-18 1991-12-18 Tricomponent formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3334854A JPH05262660A (en) 1991-12-18 1991-12-18 Tricomponent formulation

Publications (1)

Publication Number Publication Date
JPH05262660A true JPH05262660A (en) 1993-10-12

Family

ID=18281965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3334854A Pending JPH05262660A (en) 1991-12-18 1991-12-18 Tricomponent formulation

Country Status (1)

Country Link
JP (1) JPH05262660A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1069A (en) * 1996-06-13 1998-01-06 Arusoa Oushiyou:Kk Binder for processed food and processed food using the same
JPH1070A (en) * 1996-06-13 1998-01-06 Arusoa Oushiyou:Kk Processed food useful for beauty and health
WO2006003965A1 (en) * 2004-06-30 2006-01-12 Daiichi Sankyo Healthcare Co., Ltd. Skin-whitening compositions
JP2016056175A (en) * 2014-09-10 2016-04-21 株式会社東洋新薬 KAEMPFERIA PARVIFLORA-CONTAINING PPARγ EXPRESSION PROMOTING COMPOSITIONS
EP2977051A4 (en) * 2013-03-01 2016-10-05 Kim S Korean Ginseng Co Ltd Ginsenoside composition

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1069A (en) * 1996-06-13 1998-01-06 Arusoa Oushiyou:Kk Binder for processed food and processed food using the same
JPH1070A (en) * 1996-06-13 1998-01-06 Arusoa Oushiyou:Kk Processed food useful for beauty and health
WO2006003965A1 (en) * 2004-06-30 2006-01-12 Daiichi Sankyo Healthcare Co., Ltd. Skin-whitening compositions
EP2977051A4 (en) * 2013-03-01 2016-10-05 Kim S Korean Ginseng Co Ltd Ginsenoside composition
JP2016056175A (en) * 2014-09-10 2016-04-21 株式会社東洋新薬 KAEMPFERIA PARVIFLORA-CONTAINING PPARγ EXPRESSION PROMOTING COMPOSITIONS

Similar Documents

Publication Publication Date Title
Freis et al. Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents
DE69828881T2 (en) COMPOSITION TO TREAT DISORDERS OF HUMAN HEALTH IN HEALTHY INDIVIDUALS
Lindén Vitamin D and myocardial infarction
US4496548A (en) Composition and method for reducing hangover
RU2368385C2 (en) Ginkgo complexes used for strengthening cognitive functions and decreasing mental fatigue
US4393078A (en) Bupropion and ethanol
WO1991000730A1 (en) A slimming pharmaceutical composition
US20180104248A1 (en) Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
JP5697835B2 (en) Oral preparation for preventing or improving dry skin
White et al. A pharmacokinetic comparison of two delayed-release peppermint oil preparations, Colpermin and Mintec, for treatment of the irritable bowel syndrome
WO1995007690A1 (en) Composition and method for treating nicotine craving in smoking cessation
CN101172105A (en) Use of levetiracetam in preparing intelligence benefiting medicament
Bianco et al. The effect of thymoxamine on histamine induced bronchospasm in man
JPH05262660A (en) Tricomponent formulation
Hueper CINCHOPHEN:(Atophan): A Critical Review
Minto et al. “Temposil” a new drug in the treatment of alcoholism
DK165966B (en) IMPROVED PIROXICAM CONTAINING ANTI-INFLAMMATORY PREPARATION
US4539315A (en) Sublingually absorbable nontoxic aspirin composition
Touger-Decker et al. Position of the American Dietetic Association: the impact of fluoride on health
JPH0436136B2 (en)
US5948824A (en) Use of a chemical agent for reducing the changes in waistline and the effect of constipation due to the taking of other agents
CA3064193C (en) Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
Kiersch et al. The onset of action and the analgesic efficacy of Saridon®*(a propyphenazone/paracetamol/caffeine combination) in comparison with paracetamol, ibuprofen, aspirin and placebo (pooled statistical analysis)
Ravid et al. The relative antihypertensive potency of propranolol, oxprenolol, atenolol, and metoprolol given once daily: a double-blind, crossover, placebo-controlled study in ambulatory patients
CA1089366A (en) Treatment of asthma